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Original Article

Multicenter Trial of a Combination Probiotic
for Children with Gastroenteritis
Stephen B. Freedman, M.D.C.M., Sarah Williamson‑Urquhart, B.Sc.Kin.,
Ken J. Farion, M.D., Serge Gouin, M.D.C.M., Andrew R. Willan, Ph.D.,
Naveen Poonai, M.D., Katrina Hurley, M.D., Philip M. Sherman, M.D.,
Yaron Finkelstein, M.D., Bonita E. Lee, M.D., Xiao‑Li Pang, Ph.D., Linda Chui, Ph.D.,
David Schnadower, M.D., M.P.H., Jianling Xie, M.D., M.P.H., Marc Gorelick, M.D.,
and Suzanne Schuh, M.D., for the PERC PROGUT Trial Group*

A BS T R AC T
BACKGROUND

Gastroenteritis accounts for approximately 1.7 million visits to the emergency department (ED) by children in the United States every year. Data to determine whether the use
of probiotics improves outcomes in these children are lacking.
METHODS

We conducted a randomized, double-blind trial involving 886 children 3 to 48 months of
age with gastroenteritis who presented to six pediatric EDs in Canada. Participants received a 5-day course of a combination probiotic product containing Lactobacillus rhamnosus R0011 and L. helveticus R0052, at a dose of 4.0×109 colony-forming units twice daily or
placebo. The primary outcome was moderate-to-severe gastroenteritis, which was defined
according to a post-enrollment modified Vesikari scale symptom score of 9 or higher
(scores range from 0 to 20, with higher scores indicating more severe disease). Secondary
outcomes included the duration of diarrhea and vomiting, the percentage of children who
had unscheduled physician visits, and the presence or absence of adverse events.

The authors’ affiliations are listed in the
Appendix. Address reprint requests to Dr.
Freedman at the Sections of Emergency
Medicine and Gastroenterology, Depart‑
ment of Pediatrics, Alberta Children’s Hos‑
pital and Research Institute, University of
Calgary, 2888 Shaganappi Trail NW, Cal‑
gary, AB T3B 6A8, Canada, or at stephen
.freedman@albertahealthservices.ca.
* A complete list of the members of the
PERC PROGUT Trial Group is provided
in the Supplementary Appendix, avail‑
able at NEJM.org.
N Engl J Med 2018;379:2015-26.
DOI: 10.1056/NEJMoa1802597
Copyright © 2018 Massachusetts Medical Society.

RESULTS

Moderate-to-severe gastroenteritis within 14 days after enrollment occurred in 108 of 414
participants (26.1%) who were assigned to probiotics and 102 of 413 participants (24.7%)
who were assigned to placebo (odds ratio, 1.06; 95% confidence interval [CI], 0.77 to
1.46; P = 0.72). After adjustment for trial site, age, detection of rotavirus in stool, and
frequency of diarrhea and vomiting before enrollment, trial-group assignment did not
predict moderate-to-severe gastroenteritis (odds ratio, 1.06; 95% CI, 0.76 to 1.49; P = 0.74).
There were no significant differences between the probiotic group and the placebo group
in the median duration of diarrhea (52.5 hours [interquartile range, 18.3 to 95.8] and
55.5 hours [interquartile range, 20.2 to 102.3], respectively; P = 0.31) or vomiting (17.7
hours [interquartile range, 0 to 58.6] and 18.7 hours [interquartile range, 0 to 51.6],
P = 0.18), the percentages of participants with unscheduled visits to a health care provider (30.2% and 26.6%; odds ratio, 1.19; 95% CI, 0.87 to 1.62; P = 0.27), and the percentage of participants who reported an adverse event (34.8% and 38.7%; odds ratio, 0.83;
95% CI, 0.62 to 1.11; P = 0.21).
CONCLUSIONS

In children who presented to the emergency department with gastroenteritis, twice-daily
administration of a combined L. rhamnosus–L. helveticus probiotic did not prevent the development of moderate-to-severe gastroenteritis within 14 days after enrollment. (Funded
by the Canadian Institutes of Health Research and others; PROGUT ClinicalTrials.gov
number, NCT01853124.)
n engl j med 379;21
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A Quick Take
is available at
NEJM.org

cute gastroenteritis accounts for
approximately 1.7 million emergency department (ED) visits among children in the
United States every year.1 Although health care
providers traditionally have had little to offer to
modify the disease course,2 probiotics are an
expanding multibillion-dollar industry3 with potential clinical benefits.4 Consumers increasingly
take probiotics to treat intestinal infections,5,6
and 5 of 12 leading guidelines endorse the use
of probiotics.7 Most studies of probiotics with
results that have been published have had methodologic limitations and small sample sizes, have
included limited investigations of causative pathogens, and have not reported adverse events.8
Numerous individual symptoms have been used
as outcomes, but evaluations that incorporate both
the duration and frequency of both diarrhea and
vomiting are lacking.9 Given the distressing symptoms of gastroenteritis10,11 and the lack of benefit
of probiotics shown in one North American
study that enrolled children who received care in
the ED,12 the role of probiotics in outpatient
management of acute gastroenteritis in children
warrants clarification.
We conducted the Pediatric Emergency Research Canada (PERC) Probiotic Regimen for
Outpatient Gastroenteritis Utility of Treatment
(PROGUT) trial to evaluate the effectiveness of
probiotics in children 3 to 48 months of age who
present to the ED with acute gastroenteritis. We
hypothesized that the percentage of children
with moderate-to-severe gastroenteritis (defined
according to a validated severity score13,14) within
14 days after enrollment would be significantly
lower among those who received probiotics than
among those who received placebo.
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bacillus rhamnosus R0011 and L. helveticus R0052
at a dose of 4.0×109 colony-forming units (CFU)
twice daily or placebo.
Probiotic and placebo sachets were provided
free of charge by Lallemand Health Solutions,
which tested quantitative bacterial cultures obtained from unused sachets. None of the funders
had any input into the design or conduct of the
trial; the collection, management, analysis, or
interpretation of the data; the preparation, review,
or approval of the manuscript; or the decision to
submit the manuscript for publication. Research
ethics boards at the participating sites approved
the trial (see the Supplementary Appendix, available with the full text of this article at NEJM.org).
The full protocol and statistical analysis plan are
available at NEJM.org.15 All the authors vouch for
the completeness and accuracy of the data and
analyses presented and for the fidelity of the
trial to the protocol.
Trial Participants

Children 3 to 48 months of age were eligible for
participation if they presented to the ED, had
three or more episodes of watery stools in a 24hour period,16 had vomiting or diarrhea for less
than 72 hours, and had received a clinical diagnosis (i.e., by the responsible physician) of an
acute intestinal infection. Children were excluded if they or a person living in their household
had an indwelling vascular-access catheter or if
they had structural heart disease,17 were immunocompromised,18 or were receiving immunosuppressive therapy. Additional exclusion criteria were
hematochezia, bilious vomiting, a chronic gastrointestinal disorder (e.g., inflammatory bowel disease or the short gut syndrome), pancreatic dysfunction or insufficiency,19 the use of probiotics
during the preceding 14 days, an allergy to soy,
Me thods
and an inability to complete follow-up. Children
Trial Design and Oversight
who had undergone oral or gastrointestinal surIn this multicenter, randomized, double-blind, gery within the preceding 7 days or had previplacebo-controlled trial, participants with diar- ously participated in the trial were also excluded.
rhea were enrolled in six Canadian tertiary-care, Concomitant use of antibiotics was permitted.
university-affiliated, pediatric EDs. We sought to
determine whether the administration of a two- Randomization and Blinding
strain, commercially available probiotic product Random-number–generating software, accessed
(Lacidofil Strong, Lallemand Health Solutions) through a Web-based randomization system (www
would be superior to placebo at reducing the .randomize.net), which used random block sizes
severity of symptoms of acute gastroenteritis. of 4 and 6 and a 1:1 trial-group assignment ratio
Parents or guardians provided written informed stratified according to site, was used to sequenconsent for their children to participate. Partici- tially assign children to probiotics or placebo.
pants received a 5-day course of combined Lacto- The assignment sequence was restricted to the
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research pharmacy at the coordinating center
and www.randomize.net until the databases were
locked. Participants and their parents or guardians, trial and clinical staff, and specimen and
data analysts were unaware of the trial-group
assignments.
Procedures

The probiotic preparation is a lyophilized powder
containing 4.0×109 CFU of two bacterial strains
— L. rhamnosus R0011 and L. helveticus R0052 —
in a 95:5 ratio. Sachets containing placebo and
probiotics were identical in appearance, smell,
and weight. The contents of one sachet containing the probiotics or placebo, which had been
maintained at a temperature between 0° and
25°C, were sprinkled into 30 ml of the child’s
preferred liquid twice daily.20 Five extra sachets
were included in each kit to enable repeat dosing
if vomiting occurred within 15 minutes after
administration. Quantitative bacterial culture of
the investigational product was performed when
the use of each batch of the probiotic preparation
was completed (see the Supplementary Appendix).
Research assistants collected demographic data
and data on clinical characteristics and completed trial interventions in the ED. To maximize accuracy and minimize recall bias, parents
or guardians completed electronic or telephone
follow-up surveys every 24 hours until both vomiting and diarrhea had ceased in the participant
for 24 hours. Survey questions targeted clinical
symptoms, health care utilization, and adverse

events during the preceding 24-hour period. On
day 5, parents or guardians reported the adherence to the trial regimen (i.e., the number of
sachets received of the number prescribed) and
were asked to return all unused sachets for enumeration. If the two approaches to documentation of adherence differed, we determined a priori
that the sachet count would be used.
Rectal swabs, stool specimens, or both were
obtained during the enrollment visit.21 Bacterial
culture was performed locally. A multiplex nucleic acid panel that detects 15 enteric viruses,
bacteria, and parasites (Luminex xTAG Gastrointestinal Pathogen Panel) (see the Supplementary Appendix) was performed at the Provincial
Laboratory for Public Health–Alberta Public Laboratories, in Edmonton, Alberta, Canada.22
Outcomes

The primary outcome was the occurrence of
moderate-to-severe gastroenteritis, which was
defined according to a total modified Vesikari
scale symptom score of 9 or higher (scores range
from 0 to 20, with higher scores indicating more
severe disease) (Table 1, and the Supplementary
Appendix).13,24 The score was based on symptoms
during the follow-up period and was calculated
at the day 14 follow-up. The modified Vesikari
scale quantifies severity over a broad range of
symptoms and interventions,25 has been designed
for outpatients, and was validated at most of the
participating hospitals.13,14,26 The 14-day timeline
was used to capture relationships between the use

Table 1. Modified Vesikari Scale.*
Scale component

Score on the Vesikari Scale
0 Points

1 Point

2 Points

3 Points

Duration of diarrhea (hr)
Maximum no. of watery stools per 24 hr
Duration of vomiting (hr)
Maximum no. of vomiting episodes per 24 hr
Maximum recorded rectal temperature (°C)†
Unscheduled health care visit

0
0
0
0
<37.0
None

1–96
1–3
1–24
1
37.1–38.4
NA

97–120
4–5
25–48
2–4
38.5–38.9
Primary care

Treatment

None

Rehydration with
intravenous fluids

Hospitalization

≥121
≥6
≥49
≥5
≥39.0
Emergency
department
NA

*	In the modified Vesikari scale score, one variable (percent dehydration) in the original score was replaced with the vari‑
able of unscheduled health care visits to better measure the effect of acute gastroenteritis in outpatients, given that the
ability to perform frequent in-person assessments in an outpatient cohort of children can be challenging. Scores range
from 0 to 20, with higher scores indicating more severe disease. Children with a score of 9 or more were considered to
have moderate-to-severe gastroenteritis.13,14 NA denotes not applicable.
†	Temperatures were adjusted for the location of measurement: 1.1°C was added to axillary temperatures and 0.6°C was
added to oral temperatures.23
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of probiotics and differences from placebo in
the percentages of children who had prolonged
diarrhea.27 Baseline symptoms that occurred before the visit to the ED were not included in the
outcome measure.
Secondary outcomes specified a priori included the duration of diarrhea and the duration of
vomiting after enrollment; unscheduled visits to
a health care provider for vomiting, diarrhea,
dehydration, fever, or because the participant declined to drink fluids within 14 days after enrollment; and adverse events, which were coded
with the use of definitions from the Medical Dictionary for Regulatory Activities, version 19.0. Additional outcomes specified a priori included the
number of repeat visits to the ED, intravenous
rehydration, hospitalization, the number of days
of work missed by parents or guardians, and the
number of days of day care missed by participants.
Statistical Analysis

We assumed that moderate-to-severe gastroenteritis would occur in 25% of the children who
received placebo.13,14 At a significance level of 5%,
we calculated that a sample of 670 participants
would provide the trial with 90% power to detect
an absolute between-group difference of 10 percentage points in the outcome. We intended to
recruit 886 participants to allow for a rate of loss
to follow-up of 10%, a dropout rate of 5%, and
a crossover rate of 2.5%, with adjustment for
O’Brien–Fleming monitoring boundaries. Conservative boundaries, implemented with the use of
the Lan–DeMets alpha-spending function, guided
the early stopping boundary for safety or efficacy. All statistical tests of hypotheses were twosided. The data and safety monitoring committee (see the Supplementary Appendix) met after
200 and 500 participants were recruited.
All analyses were specified a priori.15 We included data from all participants who underwent
randomization, according to the intention-to-treat
principle. Multiple imputation was used to account for missing data. The model assumed that
data were missing at random and included key
baseline characteristics, trial group, and all efficacy outcomes. The overall significance level for
statistical tests of secondary and tertiary outcomes was set at 0.05. The Holm method was
used to adjust for multiple comparisons.28 Analyses were performed with SPSS software, version

2018
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24.0.0.1 (IBM), and Stata software, version 15.0
(StataCorp).
Baseline variables were summarized with the
use of standard descriptive statistics. Logistic
regression, stratified according to trial site, was
used to estimate odds ratios and 95% confidence intervals for the risk of moderate-to-severe
gastroenteritis associated with probiotics as
compared with placebo. Secondary analysis of
the primary outcome included adjustment for
other covariates identified a priori as being
prognostic of the outcomes.29 These covariates
were age, frequency of vomiting and diarrhea in
the 24-hour period before enrollment, trial site,
and rotavirus infection. We compared the percentage of participants with modified Vesikari
scores of 9 or higher after randomization, accounting for the interaction with the intervention, in subgroups according to age (<1 year vs.
≥1 year), whether the child had been exclusively
breast-fed, use of oral antibiotics in the 14 days
before enrollment, and adherence to the trial
regimen (receipt of >70% of doses prescribed).
The effect of rotavirus infection was evaluated in
a logistic-regression model through the addition
of an interaction term combining detection of
rotavirus infection and trial group. The modified Vesikari score was also analyzed as a continuous variable with the use of a linear-regression model with adjustment for site.
Secondary outcomes were adjusted for trial
site with the use of the appropriate regression
models. The durations of diarrhea and vomiting
were measured in hours and compared between
groups with the use of a linear-regression model. The outcome of duration of vomiting included only participants with three or more episodes
of vomiting in the 24-hour period before enrollment. Incidence rate ratios were analyzed to
compare the number of episodes of diarrhea and
vomiting after enrollment with the use of a
negative binomial model that included terms for
trial group, trial site, and the number of episodes of diarrhea, vomiting, or both, in the 24
hours before enrollment. The percentages of
children who had unscheduled health care visits
and any adverse event were compared with the
use of logistic-regression models. The subgroups
of children who attended day care and gainfully
employed parents or guardians were evaluated
for absenteeism with the use of the van Elteren
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2663 Patients were assessed for eligibility

1777 Were excluded
1049 Declined to participate
682 Met exclusion criteria
206 Could not complete follow-up
147 Had hematochezia, inflammatory
bowel disease, or short gut syndrome
132 Used supplemental probiotics in
preceding 14 days
60 Had structural heart disease
32 Had immunodeficiency or received
immunosuppressive therapy
26 Had family member with vascularaccess catheter or immunodeficiency
or who received immunosuppressive
therapy
26 Had bilious vomiting
25 Had allergy to soy
13 Were previously enrolled
9 Had vascular-access catheter
6 Underwent oral or gastrointestinal
surgery in preceding wk
3 Had pancreatic dysfunction
or insufficiency
46 Had other reasons

886 Underwent randomization

444 Were assigned to receive probiotics

442 Were assigned to receive placebo

30 Were excluded
18 Were lost to follow-up
12 Withdrew

29 Were excluded
10 Were lost to follow-up
19 Withdrew

414 Completed follow-up and were included
in the modified intention-to-treat analysis

413 Completed follow-up and were included
in the modified intention-to-treat analysis

Figure 1. Enrollment, Randomization, and Outcomes.
Some participants met more than one criterion for exclusion.

test.30 Exploratory analyses are described in the cebo (93.4%) completed follow-up. Among the
Supplementary Appendix.
participants for whom data on the number of
doses administered could be evaluated, the percentage of participants who received more than
R e sult s
70% of the doses prescribed did not differ signifiParticipants
cantly between the groups (295 of 383 particiFrom November 5, 2013, through April 7, 2017, pants [77.0%] in the probiotic group and 303 of
a total of 886 participants were enrolled and 378 participants [80.2%] in the placebo group).
underwent randomization (Fig. 1). A total of 414 Rotavirus A infection was identified more often
of the 444 participants who were assigned to in participants in the probiotic group than in the
receive probiotics (93.2%) and 413 of the 442 placebo group; otherwise, the trial groups were
participants who were assigned to receive pla- well matched with respect to baseline character-
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Table 2. Baseline Characteristics of the Enrolled Participants.*
Characteristic

Probiotic Group
(N = 440)

Placebo Group
(N = 437)

Median age (IQR) — mo

16.0 (10.0–24.8)

15.0 (9.5–24.0)

243 (55.2)

252 (57.7)

10.6 (9.0–13.0)

10.7 (8.8–12.6)

Male sex — no. (%)
Median weight (IQR) — kg
Exclusively breast-fed — no. (%)

23 (5.2)

Received antibiotics in previous 14 days — no. (%)
Received rotavirus vaccine — no. (%)

32 (7.3)

56 (12.7)

63 (14.4)

214 (48.6)

213 (48.7)

Median duration of illness (IQR) — hr†

42.5 (26.7–58.1)

43.8 (27.7–58.8)

Median modified Vesikari score (IQR)‡

10 (9–12)

10 (8–12)

Vomiting — no. (%)

345 (78.4)

327 (74.8)

5 (3–8)

5 (2–8)

Median no. of vomiting episodes in preceding 24 hr (IQR)§
Median no. of diarrhea episodes in preceding 24 hr (IQR)
Febrile — no. (%)¶
Median clinical dehydration scale score (IQR)‖

6 (4–8)

6 (4–9)

198 (45.0)

196 (44.9)

1 (0–2)

0 (0–2)

100/440 (22.7)

91/437 (20.8)

Received intravenous rehydration at index visit — no./total no. (%)

40/440 (9.1)

33/437 (7.6)

Admitted to hospital at index visit — no./total no. (%)

11/439 (2.5)

11/437 (2.5)

Norovirus GI or GII

102/432 (23.6)

124/428 (29.0)

Rotavirus A

124/432 (28.7)

85/428 (19.9)

Received ondansetron at index visit — no./total no. (%)

Stool testing results — no./total no. (%)**

Clostridium difficile toxin A or B

51/432 (11.8)

61/428 (14.3)

Adenovirus 40 or 41

50/432 (11.6)

45/428 (10.5)

Salmonella

11/432 (2.6)

9/428 (2.1)

*	No significant differences were observed between the groups in any of the baseline characteristics, with the exception
of positivity for rotavirus infection (P = 0.003). However, after adjustment for pairwise comparisons of 12 pathogens,
none of the differences remained significant. For variables for which data were missing, summary data are based on
the adjusted number. Four participants in the probiotic group and five in the placebo group withdrew from the trial
before they provided baseline demographic information. Additional data are provided in Table S9 in the Supplemen
tary Appendix. IQR denotes interquartile range.
†	This variable was defined according to the duration of vomiting or the duration of diarrhea before enrollment, which‑
ever was greater.
‡	Scores on the modified Vesikari scale range from 0 to 20, with higher scores indicating greater disease severity.13,14
§	The denominator for this variable was the number of children who had vomiting.
¶	Febrile was defined as a documented adjusted rectal temperature of at least 38.0°C.
‖	Scores on the clinical dehydration scale range from 0 to 8, with higher scores indicating more severe dehydration.31,32
**	A participant may have tested positive for more than one pathogen; all detected pathogens are reported. Results are
reported for the children from whom submitted specimens were obtained for analysis. Only pathogens identified in
more than 10 participants per trial group are listed.

istics (Table 2), discharge diagnoses (Table S1 in
the Supplementary Appendix), and coadministered medications (Table S2 in the Supplementary Appendix).

the probiotic group [108 of 414 participants] and
24.7% in the placebo group [102 of 413 participants]; difference, 1.4 percentage points; 95%
confidence interval [CI], −4.5 to 7.3; P = 0.65).
Regression analysis with adjustment for trial site
Primary Outcome
showed no benefit of probiotic use (odds ratio,
The percentage of participants who had a modi- 1.06; 95% CI, 0.77 to 1.46; P = 0.72) (Table 3). In
fied Vesikari score of 9 or higher after enroll- a multivariable analysis, trial-group assignment
ment was similar in the two groups (26.1% in did not predict moderate-to-severe gastroenteri2020
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Table 3. Trial Outcomes and Subgroups.*
Outcome and Subgroup

Probiotic Group

Placebo Group

Odds Ratio (95% CI)

P Value

108/414 (26.1)

102/413 (24.7)

1.06 (0.77–1.46)

0.72

Primary efficacy outcome: modified Vesikari score of ≥9†‡
All participants — no./total no. (%)
Age <1 yr — no./total no. (%)

45/134 (33.6)

48/150 (32.0)

1.01 (0.60–1.71)

0.97

Exclusively breast-fed — no./total no. (%)

   7/22 (31.8)

10/31 (32.3)

0.82 (0.18–3.61)

0.79§

Receipt of antibiotics within 14 days before index visit
— no./total no. (%)

  12/51 (23.5)

17/59 (28.8)

0.86 (0.35–2.11)

0.74¶

72/295 (24.4)

66/303 (21.8)

1.16 (0.79–1.71)

0.45

   52.5 (18.3–95.8)

   55.5 (20.2–102.3)

Adherence to trial regimen, defined as having received >70%
of doses prescribed — no./total no. (%)
Secondary efficacy outcomes
Median duration of diarrhea in 827 participants (IQR) — hr
Median duration of vomiting in 409 participants (IQR) — hr‖

0.31

17.7 (0–58.6)

18.7 (0–51.6)

Visit to health care provider — no./total no. (%)†

125/414 (30.2)

110/413 (26.6)

1.19 (0.87–1.62)

0.18
0.27

Any adverse event — no./total no. (%)**

136/414 (32.9)

152/413 (36.8)

0.83 (0.62–1.11)

0.21

Median no. of days of day care missed in 331 participants
(IQR)††

1.0 (0–2.0)

1.0 (0–2.0)

0.55

Median no. of hours of work missed by parent or guardian
of 653 participants (IQR)‡‡

0 (0–8.0)

0 (0–8.8)

0.18

Tertiary efficacy outcomes

Repeat visit to ED
No. of participants/total no. (%)†

83/414 (20.0)

76/413 (18.4)

1.11 (0.77–1.60)

0.56

With administration of intravenous fluid — no./total no. (%)†

36/414 (8.7)

26/413 (6.3)

1.57 (0.75–3.28)§§

0.23

With hospitalization — no./total no. (%)†

33/414 (8.0)

22/413 (5.3)

1.65 (0.66–4.12)¶¶

0.28

*	CI denotes confidence interval, and ED emergency department.
†	This outcome was analyzed with the use of logistic regression, and the model was adjusted for the enrollment site.
‡	Scores on the modified Vesikari scale range from 0 to 20, with higher scores indicating greater disease severity.
§	The regression analysis excluded participants from three sites, since all exclusively breast-fed children at these sites were either in one
group (either probiotic or placebo) or had the outcome of interest.
¶	The regression analysis excluded five participants from one site, since they all had the outcome of interest.
‖	Data include only participants with three or more episodes of vomiting in the 24 hours before enrollment.
**	This outcome was analyzed with the use of logistic regression, and the model was adjusted for enrollment site; however, no imputation
was performed for participants with missing data on adverse events.
††	These data, which include only children who attended day care, were analyzed with the use of the van Elteren test stratified according to
enrollment site. No imputation was performed for participants with missing data on day-care absenteeism. Attendance in day care was
defined as being cared for at least 2 half days (2.5 hours per day) per week by a relative or nonrelative, in a child care center, at home,
or in someone else’s home where there were, on average, a minimum of three children, including the index child.
‡‡	These data, which include only parents or guardians who worked, were analyzed with the use of the van Elteren test stratified according to
enrollment site. No imputation was performed for participants with missing data on work absenteeism.
§§	The regression analysis excluded participants from a single site, since none of the 11 children who had a repeat visit to the ED at this site
received intravenous fluids.
¶¶	The regression analysis excluded participants from three sites, since none of the 23 children who had a repeat visit to the ED at these sites
were admitted to the hospital.

tis (odds ratio, 1.06, 95% CI, 0.76 to 1.49; P = 0.74)
(Table S3 in the Supplementary Appendix).
No significant difference was observed in the
percentage of participants with a modified Vesikari score of 9 or higher in any of the subgroups
defined a priori (Table S4 in the Supplementary
Appendix). There was no interaction between
trial-group assignment and the age of the particin engl j med 379;21

pants (P = 0.72), antibiotic use in the preceding
14 days (P = 0.80), exclusive breast-feeding (P = 0.57),
and receipt of more than 70% of the doses prescribed (P = 0.59). The interaction between detection of rotavirus in stool and trial group was not
significant (P = 0.99) (Table S5 in the Supplementary Appendix). When the modified Vesikari score
was analyzed as a continuous variable, there was
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A Diarrhea
4.5

Placebo
Probiotic
Incidence rate ratio, 0.98 (95% CI, 0.85–1.13)
P=0.78

Mean No. of Episodes/Day

4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0

1

2

3

4

5

6

7

8

9

10

11

12

13

14

Day

B Vomiting
1.0

Probiotic
Placebo
Incidence rate ratio, 1.36 (95% CI, 1.13–1.63)
P<0.001

Mean No. of Episodes/Day

0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0

of

m e dic i n e

hours [interquartile range, 0 to 51.6] in the placebo group) (P = 0.31 and P = 0.18, respectively)
(Table 3). Although the total number of episodes
of diarrhea did not differ significantly between
the groups (incidence rate ratio, 0.98; 95% CI,
0.85 to 1.13; P = 0.78) (Fig. 2A), the number of
episodes of vomiting was significantly higher in
the probiotic group than in the placebo group
(incidence rate ratio, 1.36; 95% CI, 1.13 to 1.63;
P<0.001) (Fig. 2B). The percentage of children
who had unscheduled health care visits did not
differ significantly between the groups (30.2%
[125 of 414 children] in the probiotic group and
26.6% [110 of 413 children] in the placebo group;
odds ratio, 1.19; 95% CI, 0.87 to 1.62; P = 0.27).
An adverse event was reported in 34.8% (144
of 414) of the participants who received probiotics and 38.7% (160 of 413) of the participants
who received placebo (odds ratio, 0.83; 95% CI,
0.62 to 1.11; P = 0.21) (Table S7 in the Supplementary Appendix). Two children in the placebo
group had serious adverse events. One had a febrile seizure 6 hours after receiving the first dose
of the trial agent and 1 received a diagnosis of
Kawasaki disease 3 days after enrollment.
Exploratory Analyses

There was no evidence of an interaction between
trial group and the duration of symptoms at
Day
enrollment (P = 0.54), detection of bacteria in the
stool (P = 0.86), or modified Vesikari score beFigure 2. Episodes of Diarrhea and Vomiting, According to Trial Group.
fore enrollment (P = 0.86). However, the modiShown are the mean numbers of episodes of diarrhea (Panel A) and vomit‑
fied Vesikari scale score before enrollment was
ing (Panel B) per 24-hour period after enrollment. Data on all participants
are included, irrespective of the number of vomiting episodes that occurred
associated with the primary outcome in the rebefore enrollment. I bars denote the standard error.
gression model (odds ratio, 1.14; 95% CI, 1.06 to
1.23; P = 0.001). None of the results were significantly altered when the outcome of severe disno significant difference between the trial groups ease (i.e., a modified Vesikari score of ≥11) was
(mean [±SD], 6.0±4.6 in the probiotic group and considered (Table S8 in the Supplementary Ap5.8±4.4 in the placebo group; P = 0.44). There pendix).
was no evidence of benefit of probiotics according to the pathogen identified (Table S6 in the
Discussion
Supplementary Appendix).
In this trial involving children who had had
Secondary Outcomes
symptoms of gastroenteritis for up to 72 hours
No significant difference between the groups and presented to the ED, a 5-day course of twicewas found with regard to the median duration daily administration of a combined probiotic
of diarrhea (52.5 hours [interquartile range, 18.3 formulation (4.0×109 CFU of a combination
to 95.8] in the probiotic group and 55.5 hours L. rhamnosus and L. helveticus) did not prevent the
[interquartile range, 20.2 to 102.3] in the placebo development of moderate-to-severe gastroenterigroup) and vomiting (17.7 hours [interquartile tis. Among these children with predominantly virange, 0 to 58.6] in the probiotic group and 18.7 ral infection, probiotics did not result in benefits
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related to secondary outcomes. Adjustment for
potential risk factors did not alter the findings.
Although the quality of evidence has been
deemed by Szajewska et al. to be “low” or “very
low,”33 many experts consider acute infectious
diarrhea to be the main indication for probiotic
use.7 Guideline recommendations vary from “not
recommended” by the Centers for Disease Control and Prevention and the National Institute
for Health and Care Excellence34,35 to “strongly
recommended” by the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.36 These recommendations are largely based
on meta-analyses such as a 2010 Cochrane review.37 Although the authors of this review identified 63 eligible studies, they deemed only 10 to
be methodologically adequate. The main finding
of the review was a reduction of 25 hours in the
mean duration of diarrhea; however, there was
significant heterogeneity (assessed with I2 values)
that may have been due to differences in the
trial populations. Seven of the included studies
recruited outpatients, and none of the studies
were performed in the United States or Canada.
A previous North American, ED-based study that
included 155 participants12 showed no significant effect of another probiotic, L. rhamnosus GG,
on any outcomes identified a priori.
The aforementioned Cochrane review showed
a reduction of 29 hours in the duration of diarrhea among children with rotavirus infection.37
In vitro and in vivo studies have revealed potential mechanisms of probiotic action against rotavirus, including the production of antimicrobial
substances, stimulation of antimicrobial peptides
and local adaptive and innate immune responses, and epithelial-cell mucin production.38 Nonetheless, no beneficial effect of probiotics was
observed in this subgroup in our trial.
Rather than emphasizing a single symptom,39
we focused on the overall severity of a constellation of symptoms associated with gastroenteritis,
quantified with the use of the modified Vesikari
scale score. This approach quantitatively balances
the frequency against the duration of symptoms.
Analysis of a composite severity measure and of
individual symptoms and subgroups of participants who were adherent to the trial regimens,
as well as other measures of effectiveness, showed
no significant difference between the groups
and consistently showed no benefit of the probiotic strains at the dose evaluated. Although we
n engl j med 379;21

studied only a single titer, the amount selected
was higher than that recommended by the manufacturer,40 and at the end of their shelf life, we
confirmed that organism counts were in the target range (6.13×109 to 9.36×109 CFU per sachet);
thus, underdosing was unlikely.
Differences in preparations of probiotics may
account for differences in outcomes across studies.
The strain ratio (95:5) and dose of the L. rhamnosus R0011 and L. helveticus R0052 used in our trial
were based on data from previous studies that
showed them to be the most economical means
to achieve the maximum benefit. This combination was selected for this trial because the strains
have been evaluated for safety41 and efficacy in
animal models and in small clinical trials involving humans.42 In vitro, the strains have been
shown to have benefits, including exopolysaccharide production,43 adhesion and barrier function,44 pathogen inhibition,45 and immune response modulation.46 In humans, the R0011
strain survives gut transit,47 and it is approved by
Health Canada to treat antibiotic-associated and
acute infectious diarrhea. The R0011 strain contains the L. rhamnosus GG genes encoding the
soluble proteins p75 and p40, which promote
signaling pathways that are specific to intestinal
epithelial homeostasis.48 However, R0011 differs
from GG in pilus gene clusters; thus, the two
strains produce different functional pili.48
Our trial has several limitations. Although we
performed daily follow-up to maximize accuracy
in the ascertainment of outcomes, we cannot rule
out recall bias. The use of composite outcome
measures has been questioned, since they may
be subject to inconsistent and selective reporting
and post hoc modifications.49 To overcome these
concerns, we selected the modified Vesikari
scale, which has face, content, and construct
validity and is externally validated.13,14 Analysis
of all individual score elements supported the
conclusions based on our primary outcome.
Since we used a specific probiotic product and
dose, the conclusions cannot be generalized to
all products on the market. However, large, wellconducted clinical trials50-52 have aroused similar
concerns regarding the effectiveness of probiotics for other conditions. Nonetheless, there may
be specific indications and populations that will
benefit from alternative probiotic agents.53 Since
our trial was conducted in Canadian EDs, the
findings should be interpreted in that context
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with consideration given to local host micro
biomes and infectious pathogens. Our findings
cannot be extrapolated to longer-term use of
probiotics or other outcomes such as stunting in
regions where bacterial and protozoal infections
are more common.54
In conclusion, we found that a twice-daily,
5-day course of 4.0×109 CFU of a combined
L. rhamnosus and L. helveticus probiotic did not
prevent the development of moderate-to-severe
gastroenteritis within 14 days after enrollment
in infants and young children who had had
symptoms of gastroenteritis for up to 72 hours
and had been brought for care in the emergency
department.
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